Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.

about

The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies.

P2860

Q54215275-B0DCE30A-2C1B-4814-8DF9-17012BB1A00B

P2860

Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.

Item

http://www.wikidata.org/entity/Q49901067

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Safety and efficacy of temsiro ...... with recurrent bladder cancer.

@en

Safety and efficacy of temsiro ...... with recurrent bladder cancer.

@nl

type

Item

label

Safety and efficacy of temsiro ...... with recurrent bladder cancer.

@en

Safety and efficacy of temsiro ...... with recurrent bladder cancer.

@nl

prefLabel

Safety and efficacy of temsiro ...... with recurrent bladder cancer.

@en

Safety and efficacy of temsiro ...... with recurrent bladder cancer.

@nl

P1476

Safety and efficacy of temsiro ...... with recurrent bladder cancer

@en

P2093

Alejandro Goberna

http://www.w3.org/2001/XMLSchema#string

Anne-Laure Cazeau

http://www.w3.org/2001/XMLSchema#string

Barbara Lortal

http://www.w3.org/2001/XMLSchema#string

Christian Pfister

http://www.w3.org/2001/XMLSchema#string

Guilhem Roubaud

http://www.w3.org/2001/XMLSchema#string

Hakim Mahammedi

http://www.w3.org/2001/XMLSchema#string

Lionel Vedrine

http://www.w3.org/2001/XMLSchema#string

Loic Mourey

http://www.w3.org/2001/XMLSchema#string

Marina Pulido

http://www.w3.org/2001/XMLSchema#string

P2860

Genome sequencing identifies a basis for everolimus sensitivity

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Phase II study of everolimus in metastatic urothelial cancer.

Everolimus for advanced pancreatic neuroendocrine tumors.

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

The present and future burden of urinary bladder cancer in the world

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

P2888

s12885-018-4059-5

P304

194

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-018-4059-5

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101084723

http://www.w3.org/2001/XMLSchema#string

P698

29454321

http://www.w3.org/2001/XMLSchema#string

P932

5816357

http://www.w3.org/2001/XMLSchema#string

Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.

about

P2860

P2860

Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932